TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 359081
Drug: Mianserin 20
Normalized name: mianserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 20 mg three times daily (increased to 30 mg t.d.s. after one year)
Study: 359081
Drug: Lithium tablets
DrugBank: Lithium succinate (DB14508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium tablets once daily
Study: 21809362
Drug: BMS-790052 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-790052 (1, 10, 30, 60, and 100 mg, once-daily or 30 mg twice-daily)
Study: 19734380
Drug: Acupuncture (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (8 weekly sessions using four bilateral acupuncture points)
Study: 16455695
Drug: 20 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mug oral misoprostol solution at hourly intervals
Study: 16455695
Drug: Vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal dinoprostone gel at six hourly intervals
Study: 12677735
Drug: Intra-nasal mometasone
Normalized name: mometasone Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-nasal mometasone furoate (MF) 200 mg once daily
Study: 31613942
Drug: Feather-edge preparation
Normalized name: Gallus gallus feather
DrugBank: Gallus gallus feather (DB10420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feather-edge preparation (Group 1)
Study: 31613942
Drug: Chamfer preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamfer preparation (Group 2)
Study: 25509262
Drug: Xuebijing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing Injection (50 mL XI in 100 mL normal saline, injected twice daily for 3 days post-THA)
Study: 25509262
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine perioperative therapies only)
Study: 20333473
Drug: ECMO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECMO therapy
Study: 17697016
Drug: protease inhibitor-based
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: protease inhibitor-based antiretroviral therapy
Study: 16259547
Drug: Risperidone at
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone at flexible doses of 0.5 to 1.5 mg/day
Study: 12080281
Drug: Pyridoxine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (100 mg)
Study: 6365468
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fentiazac twice daily for 6 weeks
Study: 6365468
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg indomethacin twice daily for 6 weeks
Study: 6365468
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fentiazac twice daily for 2 weeks
Study: 6365468
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg phenylbutazone twice daily for 2 weeks
Study: 26717405
Drug: OraQuick Rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OraQuick Rapid HIV‐1/2 antibody test
Study: 11986955
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) treatment
Study: 18488812
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg delayed-released tablet (test formulation) without food
Study: 18488812
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg delayed-released tablet (test formulation) with food
Study: 18488812
Drug: Reference pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference pantoprazole 40 mg delayed-released tablet
Study: 10699344
Drug: Biojector(R) jet-injection
Normalized name: Humulin R Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biojector(R) jet-injection system
Study: 10699344
Drug: Needle injection
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle injection method
Study: 8466095
Drug: Ventolin metered-dose
Normalized name: albuterol Metered Dose Inhaler [Ventolin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin metered-dose inhaler (VMDI)
Study: 3780329
Drug: Alprazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.5 mg bid)
Study: 3281449
Drug: Ferric polymaltose
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric polymaltose at a dose of 100 mg elemental iron twice daily for 56 days (group 1a)
Study: 3281449
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered on the same schedule (group 1b)
Study: 3281449
Drug: Ferric polymaltose
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric polymaltose at a dose of 100 mg elemental iron twice daily for 56 days (group 2a)
Study: 3281449
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered on the same schedule (group 2b)
Study: 21114777
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with 5‐fluorouracil/cisplatin (FP) (arm B)
Study: 2886561
Drug: Diuretics alone
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics alone
Study: 18208835
Drug: Diuretics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics plus irbesartan
Study: 18208835
Drug: Diuretics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics plus ramipril
Study: 17010798
Drug: Famotidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (20 to 40 mg)
Study: 17010798
Drug: Famotidine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (30 mg/day for 6 months)
Study: 11767419
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (similar to the supplement in the pilot study)
Study: 9043728
Drug: Sevoflurane 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 1.0 to 1.5% (end-tidal) with nitrous oxide 66% in oxygen; anaesthesia induced with 5 mg.kg-1 thiopentone.
Study: 8330464
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg alprazolam daily
Study: 8330464
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg alprazolam daily
Study: 3487646
Drug: D-penicillamine (DP)
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-penicillamine (DP) 500 mg daily
Study: 3487646
Drug: D-penicillamine (DP)
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-penicillamine (DP) 125 mg daily
Study: 15988076
Drug: Amoxicillin (40-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40-45 mg/kg/24 h) + Sinupret (mucoregulatory remedy)
Study: 15988076
Drug: Amoxicillin (40-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40-45 mg/kg/24 h)
Study: 12848587
Drug: ALX 111
Normalized name: ALX-009
DrugBank: ALX-009 (DB17916)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALX 111 (parathyroid hormone (1-84), rhPTH (1-84))
Study: 8508724
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug counselling
Study: 3518966
Drug: Norfloxacin (NOR)
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin (NOR) 400 mg bid for 7 days
Study: 3518966
Drug: Pipemidic acid
Normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipemidic acid (PA) 400 mg bid for 7 days
Study: 16135834
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg, single intravenous infusion)
Study: 15264777
Drug: Oxiplex/SP Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiplex/SP Gel (1-3 ml) applied at the conclusion of surgery
Study: 7586105
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg i.v.)
Study: 7944469
Drug: Intraperitoneal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal treatment with MMC‐CH
Study: 7944469
Drug: No anti‐cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti‐cancer drugs (Control)
Study: 19905912
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg + Loratadine 10 mg
Study: 19905912
Drug: Beclomethasone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 200 mu g/twice daily
Study: 7636321
Drug: Combined hyperthermia
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hyperthermia and radiotherapy (30.0 Gy in 2 weeks or 34.5 Gy in 3 weeks with heat treatments)
Study: 7636321
Drug: Schedule A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A: 30.0 Gy with heat twice weekly (4 treatments)
Study: 7636321
Drug: Schedule B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B: 34.5 Gy with heat once weekly (3 treatments)
Study: 7636321
Drug: Schedule C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule C: 34.5 Gy with heat twice weekly (6 treatments)
Study: 18358541
Drug: Continuation-phase cognitive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation-phase cognitive therapy (C‐CT)
Study: 26425812
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (6 mm)
Study: 26425812
Drug: Long implants
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implants (11-15 mm) with sinus grafting
Study: 25476084
Drug: Traditional silica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional silica gel tube
Study: 22113345
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg aleglitazar
Study: 22113345
Drug: 3000 μg
Normalized name: immunoglobulin G, human 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 μg aleglitazar
Study: 17620371
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of imipenem-cilastatin (loading dose of 1 g/1 g, followed by 2 g/2 g per 24 h for 3 days)
Study: 17620371
Drug: Intermittent short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent short-term infusion of imipenem-cilastatin (1 g/1 g three times per day for 3 days, total daily dose 3 g/3 g)
Study: 17620371
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Continuous and Intermittent infusion)
Study: 15896431
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily energy intake of REE x 1.7
Study: 15896431
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily energy intake of REE x 1.3
Study: 12410192
Drug: Pamidronate (intravenous),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (intravenous), administered daily for 3 consecutive days, repeated at 3-month intervals for one year
Study: 12410192
Drug: Placebo (plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (plain saline, intravenous), administered daily for 3 consecutive days, repeated at 3-month intervals for one year
Study: 12410192
Drug: Pamidronate (intravenous)
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate (intravenous)
Study: 12410192
Drug: Placebo (plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (plain saline, intravenous)
Study: 1924666
Drug: Fluphenazine hydrochloride
Normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine hydrochloride at 5 mg, 10 mg, or 20 mg daily for 4 weeks
Study: 25754414
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix (mix 50 before breakfast and lunch plus mix 25 before dinner)
Study: 25754414
Drug: Basal-bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus therapy (insulin glargine at bedtime plus prandial insulin lispro thrice-daily)
Study: 25754414
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix
Study: 14691621
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tramadol (intraarticular)
Study: 14691621
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tramadol (intraarticular)
Study: 14691621
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tramadol (intraarticular)
Study: 14691621
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tramadol (intravenous)
Study: 14691621
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tramadol (intravenous)
Study: 14691621
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tramadol (intravenous)
Study: 6741804
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (STK)
Study: 31780038
Drug: Synbiotics (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (500 mg capsule containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum plus inulin)
Study: 22531205
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate administration (minimum 750 mg/d)
Study: 22531205
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of sodium valproate administration
Study: 19963274
Drug: Quetiapine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (average daily dose=232mg)
Study: 15034229
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate 2 mg
Study: 12941063
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three compounds (Climodien, Estradiol valerate, Placebo)
Study: 8787364
Drug: Acellular diphtheria/pertussis/tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular diphtheria/pertussis/tetanus (ADPT) vaccines
Study: 8787364
Drug: Whole-cell diphtheria-pertussis-tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell diphtheria-pertussis-tetanus (WCDPT) vaccine
Study: 24555753
Drug: High-dose clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clarithromycin
Study: 24555753
Drug: Low-dose clarithromycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose clarithromycin
Study: 19482902
Drug: Ultrasound Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound Therapy (US)
Study: 29164826
Drug: Jessner's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jessner's solution
Study: 17136873
Drug: Loratadine plus
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine plus pseudoephedrine (L+P)
Study: 11054327
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (group C)
Study: 8627066
Drug: Proinflammatory cytokines
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proinflammatory cytokines (TNF-alpha, IL-6, IL-8) and counterinflammatory compounds (IL-10, sTNFR-55, sTNFR-75) levels
Study: 8627066
Drug: Plasminogen activator
Normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasminogen activator inhibitor (PAI)-1 levels
Study: 6588975
Drug: Clofibate 1
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofibate 1 g b.i.d.
Study: 6588975
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid 3 g/day (b.i.d. or t.i.d.)
Study: 6588975
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid 3.0 g/day (alternate to previous schedule) and gemfibrozil 1.2 g/d in divided doses
Study: 31711464
Drug: Oral Polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Polio Vaccination (OPV)
Study: 24708204
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) abatacept (125 mg weekly) with IV loading (∼10 mg/kg on Day 1)
Study: 24708204
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) abatacept (∼10 mg/kg monthly)
Study: 24708204
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) abatacept
Study: 24708204
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) abatacept
Study: 20426797
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 10 mg kg(‐1) day(‐1) for 30 days
Study: 11871383
Drug: Plain-formulated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain-formulated aspirin (PF)
Study: 11871383
Drug: Extended-release aspirin
Normalized name: aspirin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release aspirin (EX2)
Study: 11871383
Drug: Extended-release aspirin
Normalized name: aspirin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release aspirin (EX5)
Study: 11871383
Drug: Extended-release formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release formulations (EX2 and EX5)
Study: 30659553
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral examination under white light
Study: 28112412
Drug: Usual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Cognitive Stimulation Therapy control group
Study: 25497262
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of eggs (breakfast with 2 eggs)
Study: 22893555
Drug: Vinyl bags
Normalized name: vinyl neodecanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinyl bags (subgroup: birth weight <750 g)
Study: 22893555
Drug: Thermal mattress
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal mattress (subgroup: birth weight <750 g)
Study: 21059665
Drug: Ice therapy
Normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ice therapy (repeated application of crushed ice)
Study: 16542202
Drug: SLV317 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV317 (250 mg oral solution)
Study: 15991587
Drug: Level II
Normalized name: BENZOYL PEROXIDE 50 mg in 1 mL TOPICAL GEL [DermaClear Purity Cleanser Level II]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level II (Intensive Outpatient Treatment)
Study: 15991587
Drug: Level III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level III (Medically Monitored Residential Treatment)
Study: 11104556
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent carboplatin (400 mg/m², administered on day 1 of a 21-day cycle for a total of 4 cycles)
Study: 7693881
Drug: Staging laparotomy
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staging laparotomy plus treatment adaptation (adjuvant chemotherapy only in the 33% with negative laparotomy)
Study: 27281813
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fiber/d from SCF
Study: 27281813
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g fiber/d from SCF
Study: 27281813
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g fiber/d from SCF (Control)
Study: 27281813
Drug: Calcium absorption
Normalized name: Evening Primrose Oil Oral Capsule, Liquid Filled [CALCIUM ABSORPTION FOR WOMEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium absorption
Study: 24698652
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac 0.1% drop, one drop 2h preoperatively and four times daily postoperatively for 3 days
Study: 22161746
Drug: Multidisciplinary lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary lifestyle treatment (medical, nutritional, physical, and psychological counseling during 3 months)
Study: 15265352
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs and treatments for cancer pain management
Study: 3068936
Drug: Heparin DHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin DHE
Study: 27038614
Drug: ACERTO protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACERTO protocol (n = 15): 6 h preoperative fasting for solids, oral drink (200 mL of 12.5% maltodextrin) up to 2 h before anesthesia, restricted intravenous fluids (1000 mL of crystalloid fluid after surgery), preoperative immune nutrition (600 mL/day of Impact - Nestlé, Brazil) for five days prior to surgery
Study: 27038614
Drug: Traditional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional care (n = 17; control group): 6-8 h preoperative fasting, intravenous hydration until the 1st postoperative day, no preoperative immune supplementation
Study: 10923604
Drug: Ketotifen, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen, 1 mg twice a day
Study: 8736463
Drug: Nonresponders (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders (no treatment specified)